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Some isolated populations exhibit an increased prevalence of rare recessive diseases. The island of Newfoundland
is a characteristic geographic isolate, settled by a small number of families primarily during the late 1700s and
early 1800s. During our studies of this population, we identified a group of families exhibiting a retinal dystrophy
reminiscent of retinitis punctata albescens but with a substantially lower age at onset and more-rapid and distinctive
progression, a disorder that we termed “Newfoundland rod-cone dystrophy” (NFRCD). The size of one of these
families was sufficient to allow us to perform a genomewide screen to map the NFRCD locus.We detected significant
linkage to markers on the long arm of chromosome 15, in a region encompassing RLBP1, the gene encoding the
cellular retinaldehyde–binding protein. Previously, mutations in RLBP1 have been associated with other retinal
dystrophies, leading us to hypothesize that RLBP1 mutations might also cause NFRCD. To test this hypothesis,
we sequenced all coding exons and splice junctions of RLBP1. We detected two sequence alterations, each of which
is likely to be pathogenic, since each segregates with the disease and is predicted to interfere with mRNA splicing.
In contrast to some previously reported RLBP1 mutations, which yield a protein that may retain some residual
activity, each NFRCD mutation is likely to give rise to a null allele. This difference may account for the severe
phenotype in these families and exemplifies the molecular continuum that underlies clinically distinct but genetically
related entities.
Introduction
During phototransduction, the chromophore portion of
rhodopsin, 11-cis retinaldehyde, is converted to all-trans
retinaldehyde. Photoisomerized all-trans retinaldehyde
must be recycled back into 11-cis retinaldehyde, in what
is termed the “rod visual cycle.” This process involves
RLBP1 [MIM 180090], which encodes the cellular re-
tinaldehyde-binding protein (CRALBP) (Crabb et al.
1988; Sparkes et al. 1992; Intres et al. 1994). In the
retinal pigment epithelium (RPE), CRALBP associates
with the 11-cis retinol intermediate as well as with the
regenerated 11-cis retinaldehyde (Saari 2000). Because
of the primary function of CRALBP as an acceptor of
11-cis retinol during the isomerization portion of the
Received December 13, 2001; accepted for publication January 11,
2002; electronically published February 26, 2002.
Address for correspondence and reprints: Dr. Nicholas Katsanis,
McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins Uni-
versity, 600 North Wolfe Street, Jefferson Street Building, Room 2-
127, Baltimore, MD 21287. E-mail: katsanis@jhmi.edu
* The first two authors contributed equally to this work.
 2002 by The American Society of Human Genetics. All rights reserved.
0002-9297/2002/7004-0013$15.00
visual cycle (Saari et al. 2001), it is not surprising that
mutations in this gene have been associated with various
retinal dystrophies, such as Bothnia dystrophy (BD)
(Burstedt et al. 1999, 2001; Gra¨nse et al. 2001), retinitis
punctata albescens (RPA [MIM 136880]) (Morimura et
al. 1999; Katsanis et al. 2001c), retinitis pigmentosa (RP
[MIM 268000]) (Maw et al. 1997), and fundus albi-
punctatus (FA [MIM 136880]) (Katsanis et al. 2001c).
We identified six Newfoundland pedigrees with a se-
vere rod-cone–dystrophy phenotype (NFRCD), which
has an ophthalmoscopic appearance similar to that of
RPA—but with age at onset typically in the 1st decade
of life and with rapid progression, leading to legal blind-
ness by the 2d–4th decades and to a further decrease
in visual acuity (such that, by the 5th decade, the af-
fected individual is, at best, only able to count fingers).
We performed a genomewide screen with the largest of
the six pedigrees and found statistically significant link-
age to markers on the long arm of chromosome 15.
Examination of the NFRCD critical interval suggested
several candidate genes, among which was RLBP1. Be-
cause previous studies had found association with sev-
eral retinal dystrophies, we hypothesized that mutations
in this gene could be responsible for NFRCD, and we
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examined our study cohort for sequence alterations in
RLBP1. We report the identification of two splice-junc-
tion mutations that are present in different combina-
tions in six NFRCD pedigrees and that are likely to
cause disease. We also correlate the NFRCD mutations
to their resulting phenotype, in the context of other
RLBP1 mutations associated with previously identified
distinct clinical entities. In contrast to expected ho-
mozygosity due to a founder effect, each mutation is
transmitted through two different haplotypes, suggest-
ing that the Newfoundland population is more diverse
genetically than previously postulated (Bear et al. 1988).
Subjects and Methods
Subjects
Twenty-six patients (ages 5–56 years) with a distinc-
tive autosomal recessive retinal dystrophy most closely
resembling RPA were ascertained through 12 probands
referred to the Memorial University of Newfoundland
Ocular Genetics Clinic. Nineteen of these patients live
within a 10-mile radius in a Newfoundland area that,
until recently, had remained isolated, being settled dur-
ing the mid-18th century by immigrants from south-
western England. During the last century, ancestors of
the two other clusters of patients migrated from this area
of Newfoundland to other parts of the island.
A detailed family history was obtained from each pro-
band, older relatives were interviewed, and archives were
searched, to establish connections between different
families. A single common ancestor has not been iden-
tified. However, 15 of the subjects are included in one
extended pedigree, and five smaller families have 2 or 3
affected individuals each. Since several surnames recur
in the earliest documentable generation, and since com-
munities in this area existed for several generations ear-
lier, it was originally assumed that there was a single
founder mutation responsible for the disease in all these
pedigrees.
Most subjects have been followed for 122 years, with
ophthalmological examination, visual-field testing (Gold-
mann or automated perimetry), color-vision testing (Is-
hihara, HRR pseudoisochromatic plates, and Farnsworth
D-15), dark-adaptation testing (Goldmann-Weekers a-
daptometer), electroretinography (ERG) (Nicolet Spirit
evoked potential with gold-foil electrodes), retinal pho-
tography, and fluorescein angiography. The ERG testing
included (a) low- and high-intensity full-field blue stimuli
in dark-adapted conditions, to elicit rod responses; (b)
maximum-intensity white stimuli, to elicit rod and cone
responses; and (c) high-intensity white stimuli in light-
adapted conditions and 30-Hz flicker stimuli, to elicit
cone responses.
Blood samples were collected, and DNA was extracted
from white blood lymphocytes, as described elsewhere
(Katsanis et al. 2000). Selected patients had plasma or-
nithine levels measured, to exclude gyrate atrophy. Each
patient—or, in the case of minors, parent—signed a con-
sent statement for participation in these investigations,
which were approved by the Human Investigation Com-
mittee of the Faculty of Medicine, Memorial University
of Newfoundland, and the Institutional Review Board for
Human Subject Research, Baylor College of Medicine.
Genotyping and Linkage Studies
A genomewide screen was performed on available
DNA samples, with fluorescently tagged, published mark-
ers (ABI Prism Linkage Mapping Set-MD10 version 2;
Applied Biosystems). The data were analyzed, and gen-
otypes were deduced by the GeneScan Analysis and Gen-
otyper software (Applied Biosystems). Linkage analysis
was performed—and haplotypes were constructed—with
data from both of the polymorphic markers flanking the
region with RLBP1 and with mutational data, as de-
scribed elsewhere (Katsanis et al. 1999; Beales et al. 2001).
Mutation Screening
Primers were designed to amplify exons and intronic
splice junctions of RLBP1 from all available DNA sam-
ples, as well as from control samples, from Newfoundland
(Katsanis et al. 2001a; also see the Web site of the Lupski
Lab). PCR products were purified, sequenced, and ana-
lyzed as described elsewhere (Katsanis et al. 2001a).
Results
Clinical Evaluation
In NFRCD, night blindness is present from infancy;
progressive loss of peripheral, central, and color vision
begins in childhood and results in severe visual loss by
the 2d–4th decade of life. Glaucoma and lens opacities
have not been identified. Bone spicule pigmentation,
characteristic of RP, is not seen, disks are either normal
or minimally pale until a late stage, and only mild at-
tenuation of retinal vessels is observable until the disease
is advanced. In striking contrast to BD, the maculae are
normal or exhibit a “beaten-bronze” atrophy.
A perimacular ring of white stippling similar to that in
RPA is observed in young patients, and a scallop-bordered
lacunar atrophy of the midperipheral RPE develops over
time. This is similar in appearance to early gyrate atrophy
or choroideremia; however, plasma ornithine levels are
normal, cataracts have not been documented, and myopia
is not consistently seen. Because of the common geo-
graphic origin of our subjects, the relationships estab-
lished through family history and archival searches, and
the opportunity that we had to examine patients over an
extended period of time (up to 25 years), it became clear
Figure 1 Fundus appearance at early, middle, and late stages of NFRCD. The left eyes of NF-001-p09, at age 54 years, exhibiting RPA
and scallop-bordered atrophy inferonasally (A and B), of NF-001-p24 at age 34, with RPA (C), of NF-004-p02, at age 66 years, with peripheral
lacunar atrophy (D), and of NF-001-p18, at ages 27 years (E) and 46 years (F), showing progression from RPA to advanced atrophy. Also
shown is a composite of the fundus of NF-001-p18, at age 27 years (G).
Table 1
Clinical and Electrophysiologic Characteristics of Patients with NFRCD
CASE
AGE
(years)
REFRACTION
VISUAL
ACUITYa COLOR-VISION DEFECT VISUAL FIELDb
DARK ADAPTATION
[AGE, IN YEARS]
(log units)
ERGc
(mv)
When
Studied
When Blindness
Was Registered Rod Rod/Cone Cone Flicker
3-p03 8 … Plano 6/7.5; 6/12 … Normal … … … … …
5-p02 12 … … 6/15; 6/18 Strong R/G Ring scotoma 5-25 … NR !10 !10 !10
1-p01 13 … Myopia 6/18; 6/18 Mild R/G, B/Y Ring scotoma 10-25 4.5 [12] NR 61.5 … 55
5-p01 17 … … 6/18; 6/21 Mild R/G, B/Y Central 10  peripheral islands … NR NR 12.5 11
3-p04 19 … … 6/12; CF Strong R/G Ring scotoma 10-25 … NR 28.6 14.0 NR
1-p02 23 6 High myopia 6/60; 6/90 Strong R/G, B/Y Constricted to 10 4.5 [10] NR NR NR NR
1-p31 25 16 Myopia CF; CF Strong R/G, B/Y 15 central scotoma 4 [18] … … … …
6-p01 27 20 High myopia 6/60; 6/120 … !1 central  peripheral islands … NR NR 14 10
1-p32 29 29 High myopia HM; HM No color perception Ring scotoma 5-30 at age 11 4 [11] … … … …
1-p38 32 … Myopia 6/21; 6/21 Strong R/G, B/Y Ring scotoma 1-20 4 [16] NR 46.2 26.9 34.2
1-p45 34 34 High myopia 6/60; 6/60 Strong R/G, B/Y Peripheral islands only 4.5 [19] NR 19.7 19.6 12
1-p16 40 … Plano 6/6; 6/6 Mild R/G Ring scotoma 3-30 4.5 [33] NR NR 27.3 28.9
1-p44 40 40 High myopia HM; 6/60 Strong R/G, B/Y Ring scotoma 5-25 (G III 4) … NR 22.7 18.6 16.8
8-p02 40 … High myopia 6/120; 6/9 No color perception Central scotoma  peripheral constriction … … … … …
1-p47 45 … Hyperopia 6/9; 6/9 Strong R/G, B/Y … 4.5 [32] … … … …
1-p18 46 46 Plano 6/60; 6/18 Moderate R/G, B/Y Peripheral islands only 4.5 [33] NR NR 11.3 NR
6-p03 48 35 Hyperopia CF; CF … … … … … … …
1-p24 49 … Hyperopia 6/60; 6/30 Strong R/G, B/Y Ring scotoma 1-30 4.5 [34] NR NR 50.7 35.9
1-p39 50 31 Hyperopia 6/120; 6/120 Strong R/G, B/Y Peripheral islands only 4.5 [35] NR NR NR NR
8-p01 52 45 Plano 6/120; 6/120 Strong R/G, B/Y Peripheral islands only … NR NR NR NR
4-p01 55 !55 Myopia HM; HM … Peripheral islands only (G V 4) … … … … …
3-p05 56 31 Hyperopia HM; HM … Peripheral islands only (G V 4) 5 [56] NR NR NR NR
1-p09 58 51 Myopia CF; CF Strong R/G, B/Y Central 10  peripheral islands 4.5 [54] NR NR NR NR
6-p02 62 24 … PL; PL … No response … … … … …
4-p03 63 51 Plano CF; CF Strong R/G, B/Y Central  superior scotoma (G III 4) 4 [48] NR … 15 7.1
4-p02 66 53 High myopia 6/90; 6/120 Strong R/G, B/Y Peripheral islands only … NR NR NR NR
NOTE.—Ellipses (…) denote that data were not available.
a CF p counting of fingers; HM p hand motions; PL p perception of light.
b G III 4 and G IV 4 p object size (in terms of Goldmann perimeter).
c NR p no response.
Eichers et al.: RLBP1 Splice-Site Mutations Cause NFRCD 959
Figure 2 Visual-field defects in NFRCD with Goldmann perimeter: NF-001-p16, at age 26 years, with visual acuity 6/6, showing ring
scotoma at 6–25 degrees (a), NF-001-p24, at age 34 years, with visual acuity 6/15, ring scotoma at 1–30 degrees (b), NF-001-p09, at age 54
years, with visual acuity 6/60, showing the central 10 degrees and peripheral islands only (c), and NF-004-p01, at age 57 years, with visual
acuity restricted to detection of hand motion, peripheral islands only (d).
that the different retinal appearances were part of a con-
tinuum of a single disease process (fig. 1 and table 1).
The ERG rod responses are selectively reduced early,
and the ERG rod and cone responses are both extin-
guished in advanced disease. Two young patients had a
negative photopic B-wave response at first ERG test but
later had significantly delayed and reduced responses to
photopic white and flicker stimuli. When tested, dark ad-
aptation thresholds during the teen years were typically
raised 4–4.5 log units. In most subjects, the early visual-
field defect is a ring scotoma close to fixation (fig.
2)—rather than in the midperipheral field, as in classic
RP. Central visual acuity may be good (e.g., 6/6–6/21),
although the central field may be only 1–3. The rate at
which the ring scotoma widens and becomes a complete
central scotoma determines the age at registration of
blindness and is an indicator of the rate of progression
of the disease, which may otherwise appear to be arrested.
Color-vision defects are initially mild red/green (R/G)
or mild R/G and blue/yellow (B/Y) defects, but these
progress rapidly to severe R/G and B/Y defects, by the
20s, and to eventual loss of color perception; however,
there are exceptions in which patients in their 30s or
40s have only mild-to-moderate color-vision defects re-
corded. A summary of ophthalmic findings is provided
in table 1.
Genotyping and Linkage Studies
We performed a genomewide screen with kindred NF-
001 (fig. 3). After evaluating 285/385 markers (74% of
the genome), we detected a LOD score of 5.80, at re-
combination fraction (v) 0.001, with microsatellite
D15S127. The next-closest marker tested,D15S205, 7.9
cM proximal to D15S127, also provided a positive, al-
though not statistically significant, LOD score of 2.44
at v p 0.10, suggesting that NFRCD likely maps to
15q26, close to D15S127. Haplotype analysis of all
available family members of NF-001 indicated that
NFRCD maps distal to D15S205, on the basis of a re-
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Figure 3 Mutation and haplotype data for six Newfoundland pedigrees diagnosed with NFRCD. All individuals were genotyped for
D15S205 and D15S127 and were sequenced for RLBP1. Haplotypes were then constructed for D15S205-SpliceMut1-SpliceMut2-D15S127,
with polymorphic alleles expressed in terms of base pairs. SpliceMut1 p 324GrA; SpliceMut2 p IVS32 TrC. Each colored bar represents
a unique haplotype: yellowp 135-324GrA-wt-142; bluep 124-324GrA-wt-134; redp 159-wt-IVS32 TrC-136; greenp 135-wt- IVS32
TrC-140; gray p non–disease-associated haplotypes.
combination, between D15S205 and D15S127, that is
apparent in individual p01 (fig. 3). Given that the peak
LOD score for D15S205 was at v p 0.10 and that
D15S127 is almost 8 cM away, we examined the ge-
nomic sequence between these loci for candidate genes.
RLBP1 maps within the 2-cM region of interest sur-
rounding D15S127. Mutations in RLBP1 have been im-
plicated previously in several retinal dystrophies that
share some features with the NFRCD phenotype (table
2). We thus sequenced the seven coding exons ofRLBP1,
including splice junctions, in affected individuals from
NF-001. We identified two alterations that were likely
pathogenic (fig. 4A). The first alteration was a GrA
transition (324GrA) in the last base of exon 3. The
second alteration was a TrC transition in the second
base of intron 3 (IVS32 TrC). Both alterations are
likely to interfere with splicing of the RLBP1 RNA. The
last base of an exon is a guanine in 73% of known genes
(Mount 1982) but is an adenine in only 9%, whereas
the second base of the intron is almost always a thymine
(Mount 1982; Zhang 1998).
We investigated each alteration for a potential patho-
genic effect. First, we sequenced all the family members
of NF-001 and segregated the two alterations in the ped-
igree (fig. 3). All affected individuals—but none of the
unaffected parents or siblings—either were homozygous
for one alteration or the other or were compound het-
erozygotes for both (fig. 4B). Furthermore, the IVS32
TrC alteration was not found in 106 control chromo-
somes from Newfoundland; in one control individual,
324GrA was found in the heterozygous state, which may
reflect a higher carrier frequency of this allele in New-
foundland. Third, analysis by the Delila program (see the
Delila Server Entry Page), an information-based theory
Eichers et al.: RLBP1 Splice-Site Mutations Cause NFRCD 961
Table 2
Phenotypic Spectrum of RLBP1 Mutations
Mutation 1 Mutation 2 Phenotype(s) Reference(s)
R150Q R150Q FA, RPA, RP Maw et al. (1997); Katsanis et al. (2001c)
R233W R233W BD, RPA Burstedt et al. (1999, 2001); Morimura et al. (1999); Gra¨nse et al. (2001)
9483delC 9483delC RPA Morimura et al. (1999)
M225K IVS32 TrC RPA Morimura et al. (1999)
IVS32 TrC IVS32 TrC NFRCD Present study
IVS32 TrC 324GrA NFRCD Present study
324GrA 324GrA NFRCD Present study
model of donor and acceptor splice sites, assigned a bit
value as a representation of the strength of interaction
between the splice site and the spliceosome, for both the
wild-type and the mutant splice sites (Rogan and Schnei-
der 1995; Rogan et al. 1998). The results suggest that
each of these mutations unmasks a cryptic splice site (of
5.1 bits) that is 5 bases into intron 3 and that competes
with the normal splice site (for 324GrA, the bit value
drops from 10.4 to 7.4 bits; for IVS32 TrC, the bit
value drops from 10.4 to 3.0 bits). By conceptual trans-
lation, abnormal splicing will cause a frameshift that leads
to premature termination early in exon 4 (fig. 4A), if the
mRNA is not degraded. Finally, previous studies have
shown that IVS32 TrC causes RPA in a compound
heterozygote carrying a second, missense mutation, re-
sulting in a methionine-to-lysine change (M225K) (Mor-
imura et al. 1999). We therefore concluded that these
alterations likely represent disease-associated mutations
and are not benign polymorphisms.
To evaluate further the potential involvement of
RLBP1 in NFRCD, we sequenced DNA from individ-
uals in five smaller NFRCD pedigrees; ancestors of all
six pedigrees came from a defined area within a 10-mile
radius. Although we anticipated a potential founder ef-
fect in Newfoundland, we could not identify a single
common ancestor through archived genealogical infor-
mation. The patients in NF-003, NF-004, and NF-006
were homozygous for 324GrA. In NF-005 and NF-008,
both affected individuals were compound heterozygotes
for the two alterations seen to segregate with the disease
in NF-001 (figs. 3 and 4B). These data are consistent
with the predicted inheritance of disease chromosomes,
as determined by haplotype analysis, and further sub-
stantiate the hypothesis that RLBP1 dysfunction is re-
sponsible for the NFRCD phenotype.
Discussion
We have reported a distinct rod-cone dystrophy phe-
notype, NFRCD, in six Newfoundland families that may
be unique to that geographic area. We have detected
linkage of NFRCD to a chromosome 15q26 region en-
compassing RLBP1, a gene that previously has been as-
sociated with several disorders of the retina. Sequencing
of exons and splice junctions has revealed two patho-
genic alterations that segregate with the disease in all
pedigrees with NFRCD and that are predicted to inter-
fere with mRNA processing, suggesting thatRLBP1 dys-
function is responsible for this disorder.
NFRCD is the first instance in which patients inherit
two RLBP1 splice-junction mutations (table 2). Thus
far, primarily missense mutations have been identified
in RLBP1. A homozygous missense mutation in exon
7, 9096CrT, which causes a R233W substitution, has
been associated with both BD (Burstedt et al. 1999,
2001; Gra¨nse et al. 2001) and RPA (Morimura et al.
1999). Also, autosomal recessive RP has been associated
with a homozygous missense mutation in exon 5,
4763GrA, which causes an R150Q change (Maw et al.
1997). This same mutation also has been described in
a pedigree diagnosed with FA and RPA, depending on
the patients’ age at evaluation (Katsanis et al. 2001c).
Finally, RPA has been reported both in one patient with
a homozygous 1-bp deletion (9483delC) in exon 8 and
in a patient who is a compound heterozygote with a
splice-donor mutation in intron 3 (IVS32 TrC) and
a missense mutation in exon 6 (M225K) (Morimura et
al. 1999).
The clinical distinction between FA, RP, and RPA may
be subtle and dependent on the age at diagnosis. For
instance, a long-term study of a pedigree with a R150Q
mutation revealed that patients could be diagnosed ei-
ther with FA, during the 2d decade of life, or with RPA,
during the 4th and 5th decade (Katsanis et al. 2001c).
Therefore, although NFRCD appears to manifest early
and exhibits a rapid progression and substantial or total
loss of vision by the 4th or 5th decade of life, distinc-
tions based on age at onset are not reliable, both because
of subjective ascertainment bias and because of sub-
stantial inter- and intrafamilial variability. The lack of
macular involvement may potentially be a feature that
distinguishes between NFRCD and BD.
Likewise, genotype-phenotype correlations in these
retinal dystrophies may be difficult to detect (table 1;
also see Burstedt et al. 2001). Newfoundland-specific
variation in other genes may contribute to the severity
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Figure 4 Location of mutations in RLBP1, and pedigrees harboring the mutations. A, Two splice mutations observed at the exon 3/intron
3 junction and predicted to activate a cryptic splice site 6 bp into intron 3. This splice site will create a transcript that, if translated, will produce
a protein that terminates early in exon 4. SpliceMut1 p 324GrA; SpliceMut2 p IVS32 TrC. B, Subsets of the large pedigree NF-001 and
of pedigrees NF-005 and NF-008. Patients NF-001-p01 and NF-001-p02 are homozygous for the 324GrA mutation. NF-001-p38 is homozygous
for the IVS32 TrC mutation, whereas NF-001-p45 is heterozygous for each mutation. Patients in NF-005 and NF-008 are heterozygous for
both alterations.
of the phenotype of patients with NFRCD patients and
to clinically related entities such as BD and RPA. This
variation is not likely, however, since the RPA pheno-
type—but not the more severe NFRCD phenotype—
has been reported in different populations, including
Swedes from the Gulf of Bothnia, Saudi Arabians, In-
dians, and white Europeans of various backgrounds.
More important, if the severity of the disease reflects
variation at other loci, then we might expect that milder,
RPA-like phenotypes would also be prevalent in New-
foundland, which is not the case.
The clinical stratification of RLBP1-based mutations
is more likely to depend on the effect that the mutations
have on the protein and the cell. The impact that the
splice-junction mutations have on the mRNA is difficult
to assess directly. RLBP1 expression is restricted to the
retinal Mu¨ller cells, pineal gland, RPE, iris, cornea, and
oligodendrocytes of the optic nerve and brain (Bunt-
Milam and Saari 1983; Bridges et al. 1987; Saari et al.
1997) and is not present in peripheral-blood cells or
lymphocytes, and retinas from affected individuals are
not available. Nevertheless, each splice-junction muta-
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tion is predicted to activate a cryptic splice site in intron
3; conceptually, this activation would result in either a
truncated protein product (fig. 4A) or, more likely, deg-
radation of the incorrectly spliced transcript via non-
sense-mediated RNA decay (reviewed in Culbertson
1999; Frischmeyer and Dietz 1999; Hentze and Kulozik
1999). By contrast, missense RLBP1 mutations may
compromise the function of the protein, but are not
likely to impact the message. The reported 1-bp deletion
lies in the last exon and thus is not subject to RNA
decay (Maquat 2000; Lykke-Andersen 2001); an ex-
tended protein is the expected outcome (Morimura et
al. 1999).
Comparison of the haplotypes of the disease-carrying
chromosomes in the six pedigrees also reveals two dis-
tinct haplotypes associated with the 324GrA mutation
and two haplotypes associated with the IVS32 TrC
mutation (fig. 3). These data suggest either that both
mutations were introduced into Newfoundland through
two independent mutation events on two different chro-
mosomes or that each mutation is relatively old and has
undergone haplotype divergence. Furthermore, the
higher prevalence of the 324GrA mutation suggests
that this might be the initial mutation introduced into
that population, a hypothesis consistent with the pres-
ence of this mutation in 1/106 Newfoundland control
chromosomes and in 0/112 non-Newfoundland control
chromosomes.
These observations, coupled with the presence of two
distinct mutations within the same pedigree, suggest
that genetic homogeneity in the island of Newfoundland
may be less than what would be expected on the basis
of historical and genealogical data. This inference is
consistent with data from other recessive disorders com-
monly found in this geographic region. Recent studies
have identified four distinct Newfoundland mutations
in BBS6, one of the genes causing Bardet-Biedl syn-
drome (BBS), as well as two distinct disease-associated
haplotypes for the uncloned BBS1 locus, in what has
been termed “the Newfoundland paradox” (Katsanis et
al. 2000, 2001b; Beales et al. 2001). For BBS, this phe-
nomenon is even more pronounced, since one New-
foundland pedigree also has been shown to require two
recessive mutations at one BBS locus (i.e., BBS2), cou-
pled with a single mutation at a second BBS locus (i.e.,
BBS6), for the phenotype to manifest (Katsanis et al.
2001a).
Finally, we note that individual NF-001-p45 and both
affected individuals in pedigree NF-008 are the off-
spring of consanguineous matings, for which we might
expect a homozygous RLBP1 mutation as well as iden-
tity by descent (IBD) for markers near the locus. These
individuals, however, are heterozygous both for each of
the Newfoundland mutations and for the markers span-
ning the critical interval (figs. 3 and 4B). Therefore, IBD-
based genetic screening, a common and often successful
practice in the genetic analysis of population isolates,
would likely miss this locus. Alternative inheritance
hypotheses must therefore be considered even in pop-
ulation isolates, since genetic homogeneity may be
overestimated.
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